China drug licensing deals surge nearly 10-fold in value since 2021
Source: SeekingAlpha
2026-02-19 13:31:04 ET
More on AbbVie, AstraZeneca PLC, etc.
- Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
- Pfizer: The Rebound Looks Unsustainable
- AbbVie: Dominating Immunology While Building Oncology Upside
- Merck posts new Enflonsia RSV data in infants
- Merck reports positive phase 3 second-season RSV data for ENFLONSIA
Read the full article on Seeking Alpha
For further details see:
China drug licensing deals surge nearly 10-fold in value since 2021
CSPC Pharmaceuticals Group Ltd.
NASDAQ: CHJTF
CHJTF Trading
0.0% G/L:
$1.17 Last:
100 Volume:
$1.17 Open:
